Adverse Event reporting information can be found in the footer.

STADA Specialty and Biosimilars:
Opening doors to cost-effective, life-changing treatments

At STADA, Thornton & Ross, we offer expertise and outstanding value in Specialty Pharmaceuticals and we are continuously expanding our portfolio. Our biosimilars and specialty medicines enable improved access to treatment for patients across a broad range of therapy areas.

Nephrology

Immunology

Bone Health

Oncology

KINPEYGO® 4mg▼ (modified-release hard capsules budesonide)

Kinpeygo – the only disease-modifying treatment for use in IgA nephropathy.1

Kinpeygo : Find Out More

Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).1

Prescribing Information can be found here

UZPRUVO®▼ (ustekinumab)

Uzpruvo is STADA’s ustekinumab biosimilar and offers a cost-effective alternative to the reference product.2,3

Uzpruvo (ustekinumab) is used for the treatment of moderate to severe Crohn’s disease in adults, moderate to severe active ulcerative colitis in adults, moderate to severe plaque psoriasis in adults, moderate to severe paediatric plaque psoriasis and psoriatic arthritis in adults.2

UZPRUVO : Find Out More

Prescribing Information can be found here

MOVYMIA®▼ (teriparatide)

MOVYMIA the teriparatide biosimilar from Thornton & Ross, STADA. MOVYMIA® is indicated for adults for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.4

MOVYMIA : Find Out More

Prescribing Information can be found here

Let’s stay connected!

Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?

Sign Up Here

STADA biosimilars: Making effective medicine accessible

STADA: Caring for people’s health as a trusted partner

STADA is a leading European company, established by physicians and pharmacists. Manufacturing and distributing pharmaceuticals for more than 125 years.

Key Facts:

 

130+ years

years of heritage

18+ years

of biosimilars experience

 

~120 countries

selling STADA products

13,000+ employees

around the globe

Biosimilars – a lifeline for people with unmet medical needs:

 

Demonstrate equivalent biological activity to their corresponding reference drugs
Improve cost-effectiveness
Provide alternatives for decision makers (e.g. prescribers, regulators, payers, policymakers)
Enhance treatment accessibility for patients

Our biosimilars enable improved access to treatment for patients across a broad range of indications

What is a Biosimilar?

A biosimilar is a biologic that is highly similar to another biologic medicine:5

 

Large molecule with a complex structure

Produced from living cells

Strictly regulated biomanufacturing and quality control

Biosimilars are approved according to the same strict standards of safety, efficacy and tolerability as other medicines:5

Undergo clinical studies

Manufactured in licensed facilities

Approved using the same regulatory pathway as reference product

Biosimilars have been trusted medicines in Europe for over 15 years, since the first European biosimilar approval in 20065

Commissioning framework for best value biological medicines6

The commissioning framework for best value biological medicines sets out NHS England’s ambitions to establish a best value first approach, by accelerating and widening the adoption of best value biological medicines across the NHS.

100%

Of new patients requiring biological medicines will be initiated on the best value biological, where clinically appropriate, within 3 months following its launch

80%
At least 80% of existing patients will be on the best value biological medicine within 10 months of its launch

This framework is designed to support the NHS to achieve this.

Excerpt from NHS Commissioning framework for best value biological medicines.6
See full NHS report here

References

  1. Kinpeygo 4 mg modified release hard capsules SmPC. Last accessed: December 2025.
  2. Uzpruvo SmPC. Last accessed: December 2025.
  3. Cost of Uzpruvo and reference product (Stelara) taken from NHS DM+D. Last accessed: December 2025.
  4. Movymia 20 micrograms/80 microliters solution for injection SmPC. Last accessed: December 2025.
  5. Biosimilar Medicinces Group. Biosimilar Medicines Handbook. 3rd ed. 2016. Last accessed: December 2025.
  6. Commissioning framework for best value biological medicines . Last accessed: December 2025.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.

UK-MULT-122(6) | December 2025

This site is intended to provide information to Healthcare Professionals on Thornton & Ross products.

I am a UK Healthcare Professional

Yes     No

The information on our Healthcare Professional Website is solely intended for UK Healthcare Professionals and contains promotional information. Click here to return to our main public site.

For information on our products please visit EMC and search the product for a Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.